US 9169313
Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins
granted A61KA61K38/179A61K38/1825
Quick answer
US patent 9169313 (Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins) held by Five Prime Therapeutics, Inc. expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K38/179, A61K38/1825, A61P, A61P35/00